idecabtagene vicleucel
2seventy bio,bms
day 3 #ims2022 oral abstract session nct03361748 : karmma - phase 2 - to determine the efficacy and safety of bb2121 in refractory mm #mmsm #multiplemyeloma #curemyeloma 
Multiple Myeloma Education Platform for Myeloma Community